RPG Life Sciences Limited — Updates, 24-01-2025: Press Release

RPG Life Sciences Limited has reported strong financial results for Q3 FY25 and the nine months ending December 31, 2024. Revenue from operations reached ₹172.71 crore, marking a 12% year-over-year increase, while profit before tax (PBT) before exceptional items surged by 32% to ₹46.89 crore. For the nine-month period, revenue grew to ₹510.34 crore, also a 12% rise from the previous year, with PBT increasing by 25% to ₹125.28 crore.

EBITDA margin significantly improved from 25.9% to 30.4% year-over-year for Q3, reflecting sustained profitability driven by a robust transformation strategy focused on domestic formulations. The company is modernizing its international formulations and API businesses, which are showing positive growth trends. Management highlighted ongoing cost optimization measures, and anticipates further benefits from the strategic deployment of cash reserves, including revenue from the leasing of surplus land at their Navi Mumbai plant. Positive outlook persists, emphasizing strong operational performance and effective growth initiatives.